Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
04/2010
04/07/2010CN101690811A Concentrated freeze-dried yolk antibody composite preparation for infectious bursal disease and preparation process thereof
04/07/2010CN101690777A Formula of polygonatum chewable tablets and preparation method thereof
04/07/2010CN101690770A Preparation capable of reducing blood pressure and blood lipid and improving human immunity, and preparation method thereof
04/07/2010CN101690743A Traditional Chinese medicine biological agent for improving immunity of livestock and preparation method thereof
04/07/2010CN101690735A Complex microorganism health-protection agent and preparation method thereof
04/07/2010CN101690732A Rana chensinensis egg oil health care product and preparation method thereof
04/07/2010CN101690715A Method for preparing immunoglobulin G liposome by using milk fat globule membrane phospholipids
04/07/2010CN101690588A Composition comprising probiotics and tea extract and application thereof
04/07/2010CN101224220B Compounds for strengthening organism immunity function and application thereof
04/07/2010CN101011442B Barrenwort extract fat emulsion composition and its preparing process
04/06/2010US7692028 for treating neurological disorders such as epilepsy, neuropathic pain, bipolar disorder or migraine; 2-(2-oxo-4-propyl-1-pyrrolidinyl)butanamide; neuroprotective agent
04/06/2010US7691995 Engineered RNA precursors encoded in plasmids and/or other vectors; simple, low cost technique utilizing DNA molecule production; host cells, transgenes
04/06/2010US7691974 Botulinum neurotoxin type E having increased biological half-life for use treatment and prevention of autonomic, neuromuscular and pain disorders
04/06/2010US7691967 Smart pro-drugs of serine protease inhibitors
04/06/2010US7691894 new crystals forms of Sodium trans-4-[1-[2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenylacetyl]-(4S)-methoxy(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate pentahydrate; VLA-4 (very late antigen-4) inhibitor; therapeutic drug for disorders caused by cell adhesion; water soluble, stability
04/06/2010US7691841 Azetidine derivatives as CCR-3 receptor antagonist
04/06/2010US7691804 Administering formulation selected from a BAFF-R polypeptide or fragment; a chimeric molecule comprising a BAFF-R polypeptide or fragment fused to heterologous amino acid sequence; anti-BAFF-R antibody for inhibiting B-cell growth
04/06/2010US7691568 Antibody composition-containing medicament
04/06/2010US7691378 Treating carcinomas or adenocarcinomas using at least one anti-TNF (tumor necrosis factor) antibody
04/06/2010US7691376 monoclonal antibodies or fragment thereof which binds a cell surface glycoprotein antigen located on the surface of human multiple myeloma tumor cells; for therapeutic, screening, diagnostic and cell purification purposes
04/06/2010CA2459009C Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders
04/06/2010CA2455181C Benzimidazo[4,5-f]isoquinolinone derivatives
04/06/2010CA2361582C Immunological adjuvant compound
04/06/2010CA2358505C Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
04/06/2010CA2331274C Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof
04/06/2010CA2303477C Chimaeric adenoviruses
04/06/2010CA2188919C Monoclonal antibodies which promote central nervous system remyelination
04/03/2010CA2640416A1 Bifunctional fusion molecules for the delivery of antigens to professional antigen-presenting cells
04/01/2010WO2010036876A2 Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
04/01/2010WO2010036631A2 Compounds which selectively modulate the cb2 receptor
04/01/2010WO2010036630A2 Compounds which selectively modulate the cb2 receptor
04/01/2010WO2010035806A1 Solid pharmaceutical composition
04/01/2010WO2010035769A1 Improved antibody molecule
04/01/2010WO2010035750A1 Method for producing lipid
04/01/2010WO2010035749A1 Method for concentrating lipid
04/01/2010WO2010035675A1 Immunopotentiator or antiallergic agent
04/01/2010WO2010034740A1 (r)-3-(n,n-dimethylamino)pyrrolidine derivatives
04/01/2010WO2010034590A1 Composition for treating disease
04/01/2010WO2010034243A1 Novel gene cluster
04/01/2010WO2010017103A3 Fully human anti-human nkg2d monoclonal antibodies
04/01/2010WO2010014836A3 Tgr5 modulators and methods of use thereof
04/01/2010WO2010006125A3 2-methylene-19,26-dinor-(20r,22e,25r)-vitamin d analogs
04/01/2010WO2010000127A9 Method to induce and expand therapeutic alloantigen- specific human regulatory t cells in large-scale
04/01/2010WO2009094751A8 An anti-cancer cytotoxic monoclonal antibody
04/01/2010US20100081797 Manipulation of Cytokine Levels Using CD83 Gene Products
04/01/2010US20100081793 Therapeutic uses of humanized antibodies against alpha-4 integrin
04/01/2010US20100081706 Immunomodulatory oliogonucleotides and methods of use therefor
04/01/2010US20100081696 Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
04/01/2010US20100081686 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter
04/01/2010US20100081673 Heteroaryl antagonists of prostaglandin d2 receptors
04/01/2010US20100081670 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases
04/01/2010US20100081646 Bicyclic heteroaryl inhibitors of pde4
04/01/2010US20100081645 Tricyclic heteroaryl compounds useful as inhibitors of janus kinase
04/01/2010US20100081610 Matrix metalloproteinase inhibitors
04/01/2010US20100080854 Atopic dermatitis inducer
04/01/2010US20100080844 Method to enhance an immune response of nucleic acid vaccination
04/01/2010US20100080828 Immunogenic sequences
04/01/2010US20100080827 Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
04/01/2010US20100080826 Process for treatment of amyotrophic lateral sclerosis, rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers
04/01/2010US20100080820 Preparation of a Therapeutic Composition
04/01/2010US20100080819 Modulators of p-selectin glycoprotein ligand 1
04/01/2010US20100080816 Tolerogenic populations of dendritic cells
04/01/2010US20100080814 NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
04/01/2010US20100080801 Comprises nucleotide sequences coding antibody receptor for treating autoimmune and immunological diseases
04/01/2010US20100080787 Cosmetic or dermopharmaceutical composition comprising an enzyme which is insoluble in an aqueous medium as well as its uses
04/01/2010US20100080782 Use of probiotic lactic acid bacteria for balancing the skin's immune system
04/01/2010US20100080778 Stem cell expansion enhancing factor and method of use
04/01/2010US20100080776 Method of enhancing an immune response
04/01/2010US20100080769 Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies
04/01/2010CA2775062A1 Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers
04/01/2010CA2738598A1 Composition for treating disease
04/01/2010CA2738285A1 Method for producing lipids
04/01/2010CA2738282A1 Method for concentrating lipids
04/01/2010CA2738147A1 Solid pharmaceutical composition
04/01/2010CA2737645A1 Compounds which selectively modulate the cb2 receptor
04/01/2010CA2737639A1 Compounds which selectively modulate the cb2 receptor
03/2010
03/31/2010EP2169057A1 Double-stranded rna originating in lactic acid bacterium
03/31/2010EP2169050A1 Method for the preparation of anallergic probiotic bacterial cultures and related use
03/31/2010EP2168984A1 Human antibodies that bind human IL-12 and methods for producing
03/31/2010EP2168959A1 Pyridazinone derivative and pde inhibitor containing the same as active ingredient
03/31/2010EP2168958A1 Isoindole-Imide Compounds, Compositions And Uses Thereof
03/31/2010EP2168951A1 Azolylmethylenehydrazine derivative and use thereof
03/31/2010EP2168944A1 Amine compound and pharmaceutical use thereof
03/31/2010EP2168598A1 Method of Treatment Using Ligand-Immunogen Conjugates
03/31/2010EP2168593A1 Oral vaccine compositions
03/31/2010EP2168587A1 A method for preparing a mixture containing natural vitamin p from hippophae rhamnoides l.
03/31/2010EP2168581A2 Stable polymorph of N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
03/31/2010EP2167542A1 Neutralizing monoclonal antibody against human dll4
03/31/2010EP2167498A1 Compounds and compositions as itpkb inhibitors
03/31/2010EP2167493A1 Salts of 3- (1h-ind0l-3-yl) -4- [2- (4-methyl-piperazin-i-yl) -quinazolin-4-yl]-pyrrole-2,5-di one
03/31/2010EP2167129A2 Compounds and methods for the treatment of renal disease
03/31/2010EP2167124A1 The use of monomycolyl glycerol (mmg) as an adjuvant
03/31/2010EP2167092A2 Quinazoline derivatives as pi3 kinase inhibitors
03/31/2010EP1756111B1 Alkyl substituted indoloquinoxalines
03/31/2010EP1630165B1 [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF
03/31/2010EP1194168B1 Methods and products for manipulating uncoupling protein expression
03/31/2010CN101688183A Cancerous disease modifying antibodies
03/31/2010CN101687932A Binding members for ige molecules
03/31/2010CN101687931A an anti-cancer cytotoxic monoclonal antibody
03/31/2010CN101687930A Chimeric and humanized anti-CD44 antibodies that mediate cancer cell cytotoxicity
1 ... 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 ... 1172